Athyrium to invest $1.23bn in near-commercial companies
This article was originally published in Scrip
Executive Summary
Can't find a partner to help commercialize your Phase III drug awaiting US FDA approval? Athyrium Capital Management has raised its second fund in hopes of investing $1.23bn in such an opportunity.